TY - JOUR
T1 - Clostridioides difficile Infections
T2 - Prevention and Treatment Strategies
AU - Levy, Elvira Ingrid
AU - Dinleyici, Meltem
AU - Dinleyici, Ener
AU - Vandenplas, Yvan
N1 - © 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG.
PY - 2024
Y1 - 2024
N2 - Clostridioides difficile is the most common causative agent of antibiotic-associated diarrhea. This spore forming, obligate anaerobic, gram-positive bacillus is becoming responsible for an increasing number of infections worldwide, both in community and in hospital settings, whose severity can vary widely from an asymptomatic infection to a lethal disease. While discontinuation of antimicrobial agents and antibiotic treatment of the infection remain the cornerstone of therapy, more recent fecal microbiota transplantation has also been valid as a therapy. The use of probiotics, especially Saccharomyces boulardii CNCM I-745 have become valid forms of prevention therapy. Although there are studies in adults with microbiota-targeted new generation therapies and Clostridium difficile vaccines, there are no data in the paediatric age group yet.
AB - Clostridioides difficile is the most common causative agent of antibiotic-associated diarrhea. This spore forming, obligate anaerobic, gram-positive bacillus is becoming responsible for an increasing number of infections worldwide, both in community and in hospital settings, whose severity can vary widely from an asymptomatic infection to a lethal disease. While discontinuation of antimicrobial agents and antibiotic treatment of the infection remain the cornerstone of therapy, more recent fecal microbiota transplantation has also been valid as a therapy. The use of probiotics, especially Saccharomyces boulardii CNCM I-745 have become valid forms of prevention therapy. Although there are studies in adults with microbiota-targeted new generation therapies and Clostridium difficile vaccines, there are no data in the paediatric age group yet.
KW - Humans
KW - Clostridium Infections/prevention & control
KW - Clostridioides difficile/pathogenicity
KW - Probiotics/therapeutic use
KW - Fecal Microbiota Transplantation
KW - Anti-Bacterial Agents/therapeutic use
KW - Gastrointestinal Microbiome
KW - Diarrhea/prevention & control
UR - http://www.scopus.com/inward/record.url?scp=85199934203&partnerID=8YFLogxK
U2 - 10.1007/978-3-031-58572-2_11
DO - 10.1007/978-3-031-58572-2_11
M3 - Article
C2 - 39060738
VL - 1449
SP - 175
EP - 186
JO - Advances in Experimental Medicine and Biology
JF - Advances in Experimental Medicine and Biology
SN - 0065-2598
ER -